vs
Crexendo, Inc.（CXDO）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Crexendo, Inc.的1.7倍（$30.3M vs $18.1M），Crexendo, Inc.净利率更高（6.7% vs -221.3%，领先228.1%），REGENXBIO Inc.同比增速更快（43.0% vs 11.2%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 12.4%）
Crexendo, Inc.是一家总部位于美国的云通信技术供应商，主要面向北美市场的中小企业提供统一通信即服务、呼叫中心解决方案、商业VoIP服务及相关协同办公工具。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CXDO vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.7倍
$18.1M
营收增速更快
RGNX
高出31.8%
11.2%
净利率更高
CXDO
高出228.1%
-221.3%
两年增速更快
RGNX
近两年复合增速
12.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.1M | $30.3M |
| 净利润 | $1.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 6.3% | -190.0% |
| 净利率 | 6.7% | -221.3% |
| 营收同比 | 11.2% | 43.0% |
| 净利润同比 | 140.2% | -31.2% |
| 每股收益（稀释后） | $0.03 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CXDORGNX
| Q4 25 | $18.1M | $30.3M | ||
| Q3 25 | $17.5M | $29.7M | ||
| Q2 25 | $16.6M | $21.4M | ||
| Q1 25 | $16.1M | $89.0M | ||
| Q4 24 | $16.2M | $21.2M | ||
| Q3 24 | $15.6M | $24.2M | ||
| Q2 24 | $14.7M | $22.3M | ||
| Q1 24 | $14.3M | $15.6M |
净利润CXDORGNX
| Q4 25 | $1.2M | $-67.1M | ||
| Q3 25 | $1.4M | $-61.9M | ||
| Q2 25 | $1.2M | $-70.9M | ||
| Q1 25 | $1.2M | $6.1M | ||
| Q4 24 | $507.0K | $-51.2M | ||
| Q3 24 | $148.0K | $-59.6M | ||
| Q2 24 | $588.0K | $-53.0M | ||
| Q1 24 | $434.0K | $-63.3M |
毛利率CXDORGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CXDORGNX
| Q4 25 | 6.3% | -190.0% | ||
| Q3 25 | 7.5% | -176.3% | ||
| Q2 25 | 6.7% | -296.3% | ||
| Q1 25 | 7.2% | 13.6% | ||
| Q4 24 | 3.9% | -242.1% | ||
| Q3 24 | 0.9% | -256.6% | ||
| Q2 24 | 3.9% | -251.3% | ||
| Q1 24 | 3.4% | -408.8% |
净利率CXDORGNX
| Q4 25 | 6.7% | -221.3% | ||
| Q3 25 | 8.3% | -208.3% | ||
| Q2 25 | 7.4% | -331.8% | ||
| Q1 25 | 7.3% | 6.8% | ||
| Q4 24 | 3.1% | -241.3% | ||
| Q3 24 | 0.9% | -246.3% | ||
| Q2 24 | 4.0% | -237.7% | ||
| Q1 24 | 3.0% | -405.4% |
每股收益（稀释后）CXDORGNX
| Q4 25 | $0.03 | $-1.30 | ||
| Q3 25 | $0.05 | $-1.20 | ||
| Q2 25 | $0.04 | $-1.38 | ||
| Q1 25 | $0.04 | $0.12 | ||
| Q4 24 | $0.03 | $-0.99 | ||
| Q3 24 | $0.00 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $0.01 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $114.0K | — |
| 股东权益账面价值 | $63.8M | $102.7M |
| 总资产 | $77.7M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资CXDORGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务CXDORGNX
| Q4 25 | $114.0K | — | ||
| Q3 25 | $236.0K | — | ||
| Q2 25 | $356.0K | — | ||
| Q1 25 | $475.0K | — | ||
| Q4 24 | $592.0K | — | ||
| Q3 24 | $709.0K | — | ||
| Q2 24 | $823.0K | — | ||
| Q1 24 | $937.0K | — |
股东权益CXDORGNX
| Q4 25 | $63.8M | $102.7M | ||
| Q3 25 | $61.3M | $161.5M | ||
| Q2 25 | $58.3M | $213.7M | ||
| Q1 25 | $55.2M | $274.2M | ||
| Q4 24 | $51.4M | $259.7M | ||
| Q3 24 | $49.5M | $301.4M | ||
| Q2 24 | $48.2M | $348.3M | ||
| Q1 24 | $46.8M | $390.7M |
总资产CXDORGNX
| Q4 25 | $77.7M | $453.0M | ||
| Q3 25 | $76.0M | $525.2M | ||
| Q2 25 | $71.4M | $581.0M | ||
| Q1 25 | $67.4M | $490.9M | ||
| Q4 24 | $64.9M | $466.0M | ||
| Q3 24 | $62.3M | $519.1M | ||
| Q2 24 | $59.6M | $569.4M | ||
| Q1 24 | $57.5M | $629.2M |
负债/权益比CXDORGNX
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | 1.93× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CXDORGNX
| Q4 25 | $2.3M | $-52.3M | ||
| Q3 25 | $4.4M | $-56.0M | ||
| Q2 25 | $1.3M | $-49.3M | ||
| Q1 25 | $1.2M | $33.6M | ||
| Q4 24 | $2.2M | $-31.6M | ||
| Q3 24 | $1.6M | $-40.5M | ||
| Q2 24 | $2.7M | $-45.5M | ||
| Q1 24 | $-166.0K | $-55.5M |
自由现金流CXDORGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | $1.3M | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | $2.1M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率CXDORGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | 7.7% | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | 13.2% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度CXDORGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.2% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.0% | 3.6% |
现金转化率CXDORGNX
| Q4 25 | 1.93× | — | ||
| Q3 25 | 3.05× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | 5.53× | ||
| Q4 24 | 4.29× | — | ||
| Q3 24 | 10.95× | — | ||
| Q2 24 | 4.51× | — | ||
| Q1 24 | -0.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
